iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
For some people with early-stage hormone-receptor-positive, HER2-negative breast cancer, a guideline-supported genomic assay has a stronger clinical foundation than an AI recurrence score. These tumor tests can help estimate recurrence risk and, for some patients, inform chemotherapy decisions. The AI model covered here is promising research—not evidence that an AI score is cleared or routinely available to guide treatment. The right test depends on the cancer’s features and the decision your care team is trying to make.
At a glance
| Name | Best for | Key evidence or output | Checked |
|---|---|---|---|
| Oncotype DX | Selected early-stage HR-positive, HER2-negative cancers with 0–3 involved nodes | 21 genes; Recurrence Score from 0–100; helps estimate recurrence risk and chemotherapy benefit | Nov 2026 |
| MammaPrint | Selected early-stage cancers, including some with up to 3 positive nodes | 70 genes; low- or high-risk result to inform chemotherapy decisions | Nov 2026 |
| Prosigna | Mainly postmenopausal patients with HR-positive, HER2-negative disease | 50 genes; recurrence-risk estimate | Nov 2026 |
| EndoPredict | Selected HR-positive, HER2-negative cancers | 12 genes; recurrence-risk estimate and treatment guidance | Nov 2026 |
| Breast Cancer Index | Some patients considering endocrine therapy beyond five years | 11-gene assessment; late-recurrence risk for years 5–10 and information about possible extended endocrine-therapy benefit | Nov 2026 |
| Multimodal AI pathology model | Study of recurrence prediction across breast cancer subtypes | Combines digitized H&E slide features with clinical data; retrospective preprint results | Nov 2026 |
This is a guide to evidence and intended use, not a ranking of commercial products. The assay that fits one person may not fit another; ask the oncologist whether a result could change a specific treatment decision.
The short answer to “Should I get Oncotype DX or an AI recurrence test?” is that these are not currently interchangeable choices. Oncotype DX and other listed assays have defined clinical uses for selected patients. The AI model described here has reported prognostic performance in a preprint, but the cited evidence does not establish routine clinical deployment or treatment-guiding use. A result’s usefulness depends not just on how well a model separates higher- and lower-risk groups, but on whether it applies to the patient and helps answer a decision that matters.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWhat is the difference between an AI recurrence score and a genomic assay?
A genomic assay measures gene activity in the diagnosed tumor, while the AI model described in a 2024 preprint analyzes digitized tissue-slide images together with clinical information. Both aim to estimate cancer outcomes, but they do not measure the same things or have the same level of evidence for treatment decisions.
Popular on Amazon
- 【90 Degree Full Function USB C Adapter】Supports the latest USB4 standard for up to 40Gbps of bandwidth, 8K video support, and up to 240W Fast charging; Support USB PD 3.1 Extended Power Range (EPR) including 140W, 180W and 240W. Your productivity is easily doubled. *Warm Tip: For the best fit, please make sure the USB-C port is fully exposed; thick or bulky cases may affect compatibility.
- 【Reliable Quality】Made from high-quality, scratch-resistant aluminum alloy, delicate metal frame. get excellent wear resistance and heat dissipation. Non-Slip Design for easier insertion and removal.
- 【Small and portable】Ultra thin size, ultra compact design, a petite physique that matches the minimalist design of your modern laptops. Coming with a slim figure that won't block the port next to the one it's plugged into.
- 【Compatibility】Widely work with most usb c, thunderbolt 4/3 devices. Compatibilit for ROG Ally, Steam Deck, Switch, MacBook Pro, Quest 3 VR headset, Surface Book 2, iPhone 18/17/16/15, Samsung Galaxy S23/S22/S21, Note 20/10, Google Pixel, ChromeBook, etc.
- 【Excellence Customer Support】If you experience any issues or cable failure, simply reach out to our dedicated customer service team. We provide a prompt response within 18 hours, providing you with the necessary technical support to resolve any concerns.
The National Cancer Institute describes multigene tests as lab tests that look at the activity of genes in breast cancer cells. They are generally run on tumor tissue already removed during a biopsy or surgery, so a separate procedure is usually not needed. The specific genes and output differ by assay: some produce a numerical score, while others classify risk or estimate the likelihood of recurrence over a specified period.
The AI system combines patterns from digitized H&E pathology slides with clinical data. It was developed and evaluated using 8,161 patients across 15 cohorts from seven countries. That scale and international evaluation are relevant strengths of the preprint study, but they do not by themselves establish that the model improves patient outcomes or is ready for routine care. A slide-based model also depends on digitized image input and clinical information, unlike a lab assay that measures expression of a defined set of genes.
“Genomic test” can be confusing because it may sound like an inherited DNA test. In this setting, the listed multigene assays are tumor tests: they estimate the behavior of the cancer that has already been diagnosed. They are not the same as germline testing for inherited variants. Germline testing looks for variants such as BRCA1 or BRCA2 that can affect inherited cancer risk and may have implications beyond the current tumor. The NCI recommends genetic counseling to help determine whether inherited testing is appropriate and to interpret results. If the question is “Are these tests the same as BRCA testing?”, the answer is no.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Another important distinction is between a prognostic result and a treatment-benefit prediction. A prognostic test estimates the likelihood of an outcome, such as recurrence, in a defined context. A test that predicts treatment benefit helps estimate whether a treatment is likely to improve that outcome. Those are related but different questions. A score showing higher recurrence risk does not automatically mean chemotherapy will benefit that individual; the relevant evidence and clinical setting matter.
Which tests can help decide whether chemotherapy is worthwhile?
For selected early-stage HR-positive, HER2-negative cancers, certain genomic assays have evidence and guideline support for informing adjuvant chemotherapy decisions. They estimate risk and, in some settings, the likely benefit of chemotherapy; they do not give a certain prediction of what will happen to an individual.
The American Cancer Society explains that gene-expression tests cannot say for certain whether a cancer will come back with or without chemotherapy. Their role is to add evidence to a decision that also depends on the cancer and the person’s clinical circumstances. A low-risk category or score should not be read as a guarantee, and a higher-risk result is not, by itself, a prescription for chemotherapy.
Also popular on Amazon
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Oncotype DX is a 21-gene test that returns a Recurrence Score from 0 to 100. The evidence-supported setting described here is early HR-positive, HER2-negative disease with zero to three involved nodes. MammaPrint measures 70 genes and returns a low- or high-risk result; it is used in selected early-stage cases, including some with up to three positive nodes. These outputs are not on the same scale. A MammaPrint low/high classification cannot simply be translated into an Oncotype DX number, and a numerical score from one assay should not be compared as if it had the same meaning on another assay.
Prosigna and EndoPredict are also listed for selected HR-positive, HER2-negative disease, but their typical roles differ: Prosigna estimates recurrence risk mainly in postmenopausal patients, while EndoPredict provides a recurrence-risk estimate and treatment guidance. Breast Cancer Index serves a different decision horizon, discussed below. The ASCO biomarker guideline update describes where multiparameter assays may inform adjuvant endocrine and chemotherapy decisions. ASCO’s 2026 living-guideline summary also says no single test is preferred for every patient; in appropriate settings, integrated tools such as RSClin can be preferred over Oncotype DX alone for recurrence estimation.
This does not mean that every patient with HR-positive, HER2-negative disease needs an assay. The practical question is whether the test is supported for the person’s specific combination of receptor status, HER2 status, stage, lymph-node involvement, age, and menopausal status—and whether its result could affect the treatment discussion. If the clinical recommendation is already clear, ask whether an additional result would add useful information. If the recommendation is uncertain, ask which validated assay or integrated tool best fits the decision rather than assuming the newest or most numerical test is best.
The cited AI study reports prognostic performance, but it does not establish that its score predicts who benefits from chemotherapy or that using it to select treatment is safe. A higher discrimination statistic in a preprint comparison is not a substitute for evidence that score-guided treatment improves outcomes. For a chemotherapy decision, ask specifically whether the test has evidence tied to treatment benefit, not only whether it can rank outcomes.
Is the AI model more accurate than Oncotype DX?
The preprint reports a higher C-index for its AI model than for Oncotype DX in one comparison, but that result does not establish that AI is generally more accurate or clinically preferable. The comparison was limited to a particular dataset and endpoint, and it does not answer whether the model can safely guide treatment.
Recommended Free Tools
Across five external cohorts, the AI model’s pooled disease-free-interval C-index was 0.71 (95% confidence interval 0.68–0.75). In a direct comparison involving 858 patients, the reported C-index was 0.67 (95% CI 0.61–0.74) for the AI model and 0.61 (95% CI 0.49–0.73) for Oncotype DX. These figures are reported by the authors of the 2024 preprint.
Also popular on Amazon
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
A C-index describes how well a model ranks people by outcome risk: broadly, whether a person who has an event is assigned greater predicted risk than a person who does not. It is not a percentage chance that a particular person will recur, nor does it tell a patient’s chance of benefiting from chemotherapy. A C-index of 0.71 therefore does not mean “71% likely to recur.” Confidence intervals also matter: the reported ranges overlap, and the comparison does not demonstrate that the AI result is superior across patients, settings, or clinical decisions.
Accuracy is not a single quality measure. Readers and clinicians need to know what endpoint the model predicts, for which population, over what time period, and whether its estimates are calibrated to actual outcomes. A score may distinguish higher from lower risk yet still not provide a reliable individualized probability or help select a treatment. Ask about external validation beyond the development group, calibration, and performance in the subgroup relevant to the patient. The preprint reports results across cohorts, but the evidence described here does not resolve every question about these features or how the model performs in ordinary care.
The AI study is retrospective and presented as a preprint. The cited evidence does not show that the model improves survival, changes treatment safely, has regulatory clearance, or is routinely available in clinical practice. Its reported prognostic performance in triple-negative and HER2-positive cohorts is noteworthy as a model finding, but it does not make AI-guided adjuvant treatment established for those groups. The ASCO guideline update does not support routine use of multiparameter assays to guide adjuvant therapy in HER2-positive or triple-negative disease. Ask about disease-specific evidence and trials rather than assuming a model that includes a subtype is ready to guide its treatment.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problems“More accurate” is therefore not enough to choose a test. Ask whether the comparison was performed in a population like the patient, whether it predicted the outcome relevant to the decision, and whether the result has been linked to a safe treatment strategy. A model can be promising and still not be a clinical alternative to a validated assay.
Can a genomic test assess recurrence after five years?
Yes. Breast Cancer Index is the assay in this comparison specifically associated with estimating late-recurrence risk during years five to ten and assessing possible benefit from extending endocrine therapy beyond five years. Whether it applies depends on the cancer and the treatment decision under consideration.
That is a different question from estimating risk around initial adjuvant treatment. A test’s time horizon matters: a score intended to inform an early chemotherapy decision should not automatically be treated as an answer about late recurrence, and a late-recurrence tool does not replace an initial-treatment assessment. The NCI and ACS summaries describe Breast Cancer Index as an 11-gene assessment that includes recurrence information and endocrine-response information. Ask the oncologist whether this test, or another validated late-recurrence tool, is appropriate before changing or extending treatment.
Also popular on Amazon
- Portable and powerful USB-C HUB: BENFEI USB Type-C HUB, with super-soft and knot-free silicone woven design cable, meets most mobile office needs. Compact, lightweight, stylish, and powerful portable USB C Hub equipped with 1 x HDMI port, 1 x 100W charging, and 3 x USB ports. 18-month warranty, 24-hour response, to ensure you feel at ease when using our product.
- Design centered on comfort and reliability: Thanks to BENFEI's end-to-end in-house cable production capability, in-house PCBA and assembly capability, using the industry's most advanced silicone woven design and process, 20cm cable in length, no knots, super-soft, the HUB is easy to use in all scenarios: laptop, tablet, stand etc. Super-soft, 25000+ life cycles, to meet your daily carrying and office needs.
- 100W Charging: Support up to 90W USB C pass-through charging via Type-C port to keep your laptop powered. 10W is reserved for other interface operations. No data and video function on the Type-C port.
- 4K HDMI Display: The HDMI port supports media display at resolutions up to 4K 30Hz, keeping every incredible moment detailed and ultra vivid. Please note that the C port of the Host device needs to support video output.
- Transfer Files in Seconds: Transfer files and from your laptop at speeds up to 10 Gbps with USB A 3.2 port. Extra 2 USB A 2.0 ports are perfectly for your keyboards and mouse.
If you are approaching the five-year point on endocrine therapy, clarify what decision is being considered: estimating the chance of recurrence in years five through ten, or estimating whether extended endocrine therapy may offer benefit. Breast Cancer Index includes information relevant to both, but it does not make the treatment decision automatically. Discuss the result alongside the cancer’s features and the care team’s assessment.
How should you choose a test with your oncologist?
Start with the exact decision you need help making. A test is useful when it is supported for the cancer type and clinical setting at hand, measures an outcome relevant to the decision, and could reasonably change the care plan. These questions can help structure the discussion:
- Confirm the cancer’s features. Discuss hormone-receptor status, HER2 status, stage, lymph-node involvement, age, and menopausal status. These characteristics affect whether a genomic assay has evidence for the situation. Ask whether the test’s stated use includes the patient’s node status and disease subtype.
- Name the decision and time horizon. Is the question about chemotherapy after surgery, recurrence risk during initial treatment, or late recurrence after five years of endocrine therapy? Those are not interchangeable endpoints. A test cannot answer a different question simply because its result is called a recurrence score.
- Ask what evidence connects the result to treatment. Is the score prognostic (associated with outcome), or is there evidence that it predicts treatment benefit? Ask whether trials or guideline recommendations support using it for this decision. For chemotherapy, ask what the assay contributes beyond the clinical information already available.
- Check whether the result would change the plan. If the oncologist would recommend the same treatment regardless of the result, ask whether testing adds useful information. Do not treat a score as a stand-alone prescription. Ask how the result would be combined with clinical features and what uncertainty remains.
- For an AI score, ask about validation and governance. Request the validation cohorts, endpoint, calibration, subgroup performance, regulatory status, and local clinical availability. Ask explicitly how the score would alter treatment and what evidence supports that change. The model described here used digitized slides plus clinical data; ask whether the local workflow actually supports those inputs.
- Clarify logistics before a test is ordered. Ask what tissue or data are needed, who will arrange the test, how the result will be interpreted, and whether cost or coverage needs to be checked first. Prices, insurance coverage, turnaround times, and country-specific availability were not established in the sources cited here, so do not assume one assay is covered or available everywhere.
There are practical differences too. Genomic assays are laboratory analyses of tumor tissue, often tissue already obtained from biopsy or surgery. The cited AI model requires digitized pathology images and clinical data. The evidence cited here does not establish its regulatory status or routine availability, so someone offering an AI score should be able to explain the model, the evidence behind its use, and how the result enters care. A confident-looking number is not a substitute for those answers.
If the conversation is actually about inherited cancer risk rather than treatment of the current tumor, ask about genetic counseling and germline testing instead. A tumor recurrence assay does not answer whether a cancer-associated variant was inherited. Conversely, inherited testing does not serve as a substitute for a tumor assay intended to inform recurrence or adjuvant treatment decisions.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What should you conclude?
For a treatment decision in selected early-stage HR-positive, HER2-negative breast cancer, start by asking whether a guideline-supported genomic assay fits the patient and could change management. For a question about late recurrence after five years of endocrine therapy, ask whether Breast Cancer Index or another validated late-recurrence approach applies. Treat the cited AI recurrence model as promising research, not as an established replacement for genomic testing or oncologist judgment. It may be a valuable subject for continued validation, but current evidence does not establish it as a routinely available or treatment-guiding test.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Frequently Asked Questions
Should I get Oncotype DX or an AI recurrence test?
For selected early-stage HR-positive, HER2-negative cancers, ask whether Oncotype DX or another guideline-supported genomic assay fits your situation and could change treatment. The AI model described here is a preprint study, not an established routine alternative for treatment decisions.
Also popular on Amazon
- 【Read before You Buy】 Note: This adapter is USB 2.0 version and cannot transmit HDM, VGA, or other video signals. Nevertheless, they are fully capable of charging devices,duplicating files, and can be seamlessly integrated with USB-C earphones, wireless network adapters, and SD card adapters.
- 【Easy to Use and Safe】Thanks to modern manufacturing techniques, we've made these adapters sufficiently compact so that they can remain inserted in your device without noticeable protrusion or inconvenience. This means you don't have to constantly plug and unplug them, reducing the likelihood of wear and misalignment, and making them more convenient to carry around.
- 【Reliable Quality】Engineered for enhanced durability, durable aluminum alloy shell material,get excellent wear resistance and heat dissipation,the male USB C and female USB connectors & the male USB and female USB C connectors are designed to be plugged and unplugged up to 20000 times. Provides data transfer, device charging, memory space expansion, and additional computer peripherals.
- 【Think more for you】Do you need to connect a USB-C-enabled device to an odd device that only has USB-A ports? Then these USB-A male to USB-C female adapters are made for you.Simply insert the adapter into the USB-A port on the device, and you can instantly connect your USB-C device to the device that originally didn't have the correct connection port.
- 【Trusted xiwxi Quality and Service】As a responsible brand seller, you will receive xiwxi's 12-month Quality assurance and lifetime friendly customer service, you're not just buying a product,you're investing in peace of mind with all-round quality and exceptional customer service.
Is an AI breast-cancer risk score more accurate than a genomic assay?
The 2024 preprint reported a higher C-index for its AI model than Oncotype DX in one comparison of 858 patients, but the confidence intervals overlapped and the comparison does not establish general clinical superiority. A C-index measures ranking across a group, not an individual’s chance of recurrence or chemotherapy benefit.
Which test tells me whether I need chemotherapy?
No test can make that decision with certainty. For selected early HR-positive, HER2-negative cancers, genomic assays such as Oncotype DX and MammaPrint can help inform chemotherapy decisions. The oncologist interprets the result with the clinical context; the AI model discussed here has not been established as a treatment-selection tool.
Can a genomic test predict late recurrence after five years?
Breast Cancer Index is associated with estimating late-recurrence risk during years five to ten and assessing possible benefit from extending endocrine therapy beyond five years. Ask whether it applies to your cancer and the decision being considered.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Are these tests the same as BRCA genetic testing?
No. Tumor genomic assays assess the diagnosed cancer’s features. Germline testing looks for inherited variants such as BRCA1 or BRCA2. Genetic counseling can help determine whether inherited testing is appropriate and explain results.
Can the genomic assays’ scores be compared directly with one another?
Not as if they were the same scale: the tests examine different gene sets and may report different kinds of results, such as a numerical score or a risk category. Ask the oncologist to interpret the specific test’s output in its intended setting rather than converting one assay’s result into another’s.
Does a C-index of 0.71 mean I have a 71% chance of recurrence?
No. A C-index measures how well a model ranks outcomes across a group; it is not an individual recurrence probability. Ask for a calibrated estimate for the relevant endpoint and time period, if one is available for your situation.
Are prices, insurance coverage, or turnaround times known for these tests?
They were not established in the sources cited here and can depend on the assay, location, and insurer. Before testing, ask the care team and insurer about coverage, out-of-pocket cost, and expected timing.
The Bottom Line
Bottom line: For selected early-stage HR-positive, HER2-negative breast cancers, genomic assays have the stronger clinical and guideline foundation for informing treatment decisions. The AI pathology model is promising but remains a preprint result, not an established replacement or routine chemotherapy decision tool. Match any test to the cancer subtype, the outcome and time horizon, and the decision it could actually change.
